The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Market Overview

• The market for empagliflozin, dapagliflozin, and canagliflozin has shown steady growth, increasing from $9.41 billion in 2023 to $9.64 billion in 2024, with a compound annual growth rate (CAGR) of 2.4%.
• Key drivers include the rising prevalence of type 2 diabetes, heightened awareness of SGLT2 inhibitors, an aging population, growing obesity rates, and a focus on personalized medicine.

Growth Forecast

• The market is projected to reach $10.78 billion by 2028, growing at a CAGR of 2.8%.
• This growth will be fueled by increasing demand for oral diabetes medications, rising investments in diabetes research, heightened healthcare spending, greater awareness of pre-diabetes, and a focus on combination therapies.
• Major trends to watch include technological advancements, integration of telehealth, health data analytics, and improved patient data security.

Rising Diabetes Prevalence as a Growth Driver

• The increasing prevalence of diabetes is a significant factor driving the growth of the market. Diabetes, marked by high blood sugar levels due to ineffective insulin production or use, is exacerbated by factors like sedentary lifestyles, poor diet, genetic predisposition, and aging.
• Empagliflozin, dapagliflozin, and canagliflozin work by inhibiting the sodium-glucose co-transporter-2 (SGLT2) in the kidneys, which helps lower blood sugar levels by promoting glucose excretion through urine.
• According to the International Diabetes Federation, the number of individuals with diabetes is expected to rise to 643 million by 2030 and 783 million by 2045, driving demand for these medications.

View More On The Empagliflozin, Dapagliflozin And Canagliflozin Market Report 2024 – https://www.thebusinessresearchcompany.com/report/empagliflozin-dapagliflozin-and-canagliflozin-global-market-report

Major Market Players

• Key players in the market include Pfizer Inc., Merck & Co., Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, and GlaxoSmithKline, among others.
• These companies are leading the way in developing and delivering SGLT2 inhibitors, contributing to the market’s expansion.

Innovative Pediatric Diabetes Treatments

• Companies are expanding their product offerings to include pediatric type-2 diabetes treatments, addressing the needs of younger patients.
• In June 2024, AstraZeneca received FDA approval for Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 years and older with type 2 diabetes.
• This approval, based on the T2NOW Phase III clinical trial, highlights the effectiveness and safety of Farxiga in reducing HbA1c levels in children, marking a significant advancement in pediatric diabetes care.

Strategic Mergers and Acquisitions

• Mergers and acquisitions are shaping the market landscape. In May 2021, Sun Pharmaceutical Industries acquired the trademarks for the diabetes drugs Oxra, Oxramet, and Oxraduo from AstraZeneca.
• This acquisition enhances Sun Pharma’s market position and expands its diabetes treatment portfolio in India, offering more options to patients and increasing market share.

Market Segmentation

• The empagliflozin, dapagliflozin, and canagliflozin market is segmented by drug type, application, and distribution channel.
  • By Type: Empagliflozin, dapagliflozin, canagliflozin
  • By Application: Various therapeutic applications
  • By Channel: Hospitals, pharmacies

Regional Outlook

• North America was the largest region in the market in 2023, driven by advanced healthcare infrastructure and high diabetes prevalence.
• Asia-Pacific is expected to be the fastest-growing region, with increasing healthcare investments and rising awareness about diabetes management.

Conclusion: A Promising Future for SGLT2 Inhibitors

• The market for empagliflozin, dapagliflozin, and canagliflozin is poised for steady growth, supported by rising diabetes prevalence, innovations in diabetes care, and strategic industry developments.
• As new treatments and technologies emerge, the market will continue to evolve, offering expanded options for managing type 2 diabetes and improving patient outcomes globally.

Request A Sample Of The Global Empagliflozin, Dapagliflozin And Canagliflozin Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=18350&type=smp